Trial Site Detail

 

Drug:
Regorafenib (BAY 73-4506) + Moxifloxacin
Trial:
Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity
Conditions: Solid Tumors
Trial Status:
Ongoing, but not recruiting

 

Oklahoma University Cancer Institute

     
Oklahoma City , OK 73104
USA

 

Principal Investigator:
Contact:
Rene Y. McNall-Knapp 405-271-5311
Activation Status of this Site:
Closed
Notes about this Site:
Oklahoma University Cancer Institute Website:

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.